Michael Gelband’s iRadimed IRMD Stock Holding History

Michael Gelband’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,423	Closed	-$1.48M	–	1808
2026 Q1	$1.48M	Buy	+15,423	New	+$1.54M	0.01%	878
2024 Q4	–	Sell	-7,541	Closed	-$379K	–	1759
2024 Q3	$379K	Sell	7,541 -1,446	-16%	-$66.7K	﹤0.01%	1287
2024 Q2	$395K	Buy	+8,987	New	+$382K	﹤0.01%	1267
2019 Q4	–	Sell	-14,300	Closed	-$301K	–	1700
2019 Q3	$301K	Buy	+14,300	New	+$292K	0.01%	875

Other funds holding IRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's IRMD Position: Q2 2026 in Review

Michael Gelband sold out of iRadimed (IRMD) in Q2 2026, closing a stake of 15,423 shares — an estimated $1.48M sold.

Michael Gelband first reported a position in IRMD in Q3 2019 and held it in 4 quarters. The position peaked at $1.48M in Q1 2026. 212 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

Michael Gelband reported no remaining iRadimed position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 15,423 iRadimed shares in Q2 2026, an estimated $1.48M.
Michael Gelband first reported a position in iRadimed in Q3 2019 and held it in 4 quarters.
Michael Gelband's iRadimed position peaked at $1.48M in Q1 2026.
212 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.